Mark Verratti Myriad Genetics Inc (MYGN) insider trading activity

Mark Verratti is Chief Commercial Officer of MYRIAD GENETICS INC. Currently has a direct ownership of 289,277 shares of MYGN, which is worth approximately $5.04 Million. The most recent transaction as insider was on Oct 09, 2024, when has been sold 8,363 shares (Common Stock) at a price of $24.37 per share, resulting in proceeds of $203,806. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 289K

3.16% 3M change

15.83% 12M change

Total Value Held $5.04 Million

Mark Verratti Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Oct 09 2024	SELL Payment of exercise price or tax liability	$203,806 $24.37 p/Share	8,363 Reduced 2.81%	289,277 Common Stock
Sep 21 2024	SELL Payment of exercise price or tax liability	$29,713 $27.64 p/Share	1,075 Reduced 0.36%	297,640 Common Stock
Apr 14 2024	SELL Payment of exercise price or tax liability	$21,035 $19.55 p/Share	1,076 Reduced 0.36%	298,715 Common Stock
Mar 24 2024	SELL Payment of exercise price or tax liability	$72,168 $22.24 p/Share	3,245 Reduced 1.07%	299,791 Common Stock
Mar 22 2024	SELL Payment of exercise price or tax liability	$36,651 $22.24 p/Share	1,648 Reduced 0.54%	303,036 Common Stock
Mar 15 2024	SELL Payment of exercise price or tax liability	$77,995 $21.16 p/Share	3,686 Reduced 1.2%	304,684 Common Stock
Mar 14 2024	BUY Grant, award, or other acquisition	-	58,631 Added 15.98%	308,370 Common Stock
Oct 09 2023	SELL Payment of exercise price or tax liability	$125,573 $15.01 p/Share	8,366 Reduced 3.24%	249,739 Common Stock
Sep 26 2023	SELL Payment of exercise price or tax liability	$56,332 $15.99 p/Share	3,523 Reduced 1.35%	258,105 Common Stock
Sep 21 2023	SELL Payment of exercise price or tax liability	$18,044 $16.77 p/Share	1,076 Reduced 0.41%	261,628 Common Stock
Apr 14 2023	SELL Payment of exercise price or tax liability	$15,655 $22.27 p/Share	703 Reduced 0.27%	262,704 Common Stock
Mar 24 2023	SELL Payment of exercise price or tax liability	$63,308 $23.72 p/Share	2,669 Reduced 1.0%	263,407 Common Stock
Mar 22 2023	SELL Payment of exercise price or tax liability	$30,951 $22.91 p/Share	1,351 Reduced 0.51%	266,076 Common Stock
Mar 15 2023	BUY Grant, award, or other acquisition	-	39,405 Added 12.84%	267,427 Common Stock
Oct 09 2022	SELL Payment of exercise price or tax liability	$164,141 $19.62 p/Share	8,366 Reduced 3.54%	228,022 Common Stock
Sep 26 2022	SELL Payment of exercise price or tax liability	$42,214 $18.41 p/Share	2,293 Reduced 0.96%	236,388 Common Stock
Sep 25 2022	SELL Payment of exercise price or tax liability	$52,201 $18.69 p/Share	2,793 Reduced 1.16%	238,681 Common Stock
Sep 21 2022	SELL Payment of exercise price or tax liability	$14,180 $20.2 p/Share	702 Reduced 0.29%	241,474 Common Stock
Aug 25 2022	SELL Payment of exercise price or tax liability	$25,662 $24.89 p/Share	1,031 Reduced 0.42%	242,176 Common Stock
Apr 14 2022	BUY Grant, award, or other acquisition	-	10,000 Added 3.95%	243,207 Common Stock
Mar 24 2022	SELL Payment of exercise price or tax liability	$67,503 $25.32 p/Share	2,666 Reduced 1.13%	233,207 Common Stock
Mar 22 2022	BUY Grant, award, or other acquisition	-	19,238 Added 7.54%	235,873 Common Stock
Feb 16 2022	BUY Grant, award, or other acquisition	-	22,616 Added 9.45%	216,635 Common Stock
Oct 09 2021	SELL Payment of exercise price or tax liability	$257,539 $30.88 p/Share	8,340 Reduced 4.12%	194,019 Common Stock
Sep 26 2021	SELL Payment of exercise price or tax liability	$117,051 $33.31 p/Share	3,514 Reduced 1.71%	202,359 Common Stock

Mark Verratti

Chief Commercial Officer

Salt Lake City, UT

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells MYGN shares.

Notify only if

Value

Insider Trading

Get notified when an Myriad Genetics Inc insider buys or sells MYGN shares.

Notify only if

Operation

Value

Type

News

Receive news related to MYRIAD GENETICS INC

Track Activities on MYGN

Account